JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2004; 43:89-90
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rubin, L. J.
Right arrow Articles by Galiè, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rubin, L. J.
Right arrow Articles by Galiè, N.

Pulmonary arterial hypertension: a look to the future

Lewis J. Rubin, MD*,* and Nazzareno Galiè, MD{dagger}

* Pulmonary Vascular Center, University of California–San Diego School of Medicine, La Jolla, California, USA
{dagger} Institute of Cardiology, University of Bologna, Bologna, Italy

Manuscript received January 29, 2004; accepted February 3, 2004.

* Reprint requests and correspondence: Dr. Lewis J. Rubin, UCSD Medical Center, 9300 Campus Point Drive, M/C 7372, La Jolla, California 92037, USA.
ljrubin{at}ucsd.edu

The Third World Symposium on Pulmonary Arterial Hypertension served not only as a forum for the presentation of state-of-the art overviews of the pathobiologic and clinical aspects of pulmonary arterial hypertension (PAH), but also afforded an opportunity to the international scientific community to explore future directions of research and collaboration. This summary provides a brief overview of future directions in the field.

Abbreviations and Acronyms
  BMPR2 = bone morphogenetic protein receptor-2
  FPAH = familial pulmonary artery hypertension
  PAH = pulmonary arterial hypertension
  PDE5 = phosphodiesterase-5




This article has been cited by other articles:


Home page
HeartHome page
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Heart, March 1, 2008; 94(Suppl_1): i1 - i41.
[Full Text] [PDF]


Home page
ThoraxHome page
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
J. H. Newman, J. A. Phillips III, and J. E. Loyd
Narrative Review: The Enigma of Pulmonary Arterial Hypertension: New Insights from Genetic Studies
Ann Intern Med, February 19, 2008; 148(4): 278 - 283.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Voswinckel, B. Enke, F. Reichenberger, M. Kohstall, A. Kreckel, S. Krick, H. Gall, T. Gessler, T. Schmehl, H. A. Ghofrani, et al.
Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension: Results From Randomized Controlled Pilot Studies
J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1672 - 1681.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2004 by the American College of Cardiology Foundation.